Middletown Life

Author: Erasca, Inc.

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

April 27, 2026
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015

April 27, 2026
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

March 12, 2026
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

March 10, 2026
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

March 5, 2026
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001

February 24, 2026
Erasca to Present at Upcoming Conferences in February

February 12, 2026
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 23, 2026
Erasca Announces Pricing of Upsized Public Offering of Common Stock

January 21, 2026
Erasca Announces Proposed Public Offering of $150 Million of Common Stock

January 20, 2026